BMY

PATIENT MEDICATION OF POMALYST 3MG CAP - PHARMACY ORDER FOR THE HUNTINGTON VA MEDICAL CENTER.

PATIENT MEDICATION OF POMALYST 2MG, 3MNG, 4MG. TO BE SHIPPED TO THE BALTIMORE VA MEDICAL CENTER.

PHARMACY ORDER FOR PATIENT MEDICATION - BALTIMORE VA MEDICAL CENTER.

PATIENT MEDICATION - THALIDOMIDE 100MG - SHIP TO BALTIMORE VA MEDICAL CENTER PHARMACY.

BREYANZI CAR T-TRANSPLANT

POMALIDOMIDE(POMALYST) 4MG CAP

BRISTOL-MYERS SQUIBB, LENALIDOMIDE (REVLIMID) 20MG CAP 14 DOSES 14 X 808.52 $11319.28 FEB FY26

BRISTOL-MYERS SQUIBB, REVLIMID 20MG CAP 14 X 808.52 $11319.28 MAR FY26

POMALYST 3 MG

POMALYST 2 MG, 4 MG

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act

Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues

Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process

Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.

Issues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy.

Education about the value of biopharmaceutical innovation and related issues.

Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.